Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term ...

There is no worldwide consensus on the use of any HCC staging system. Classifications that take into account only one of the relevant prognostic parameters, such as tumor, nodes, and metastasis ...

Unfortunately, even with the use of US contrast agents, there is considerable overlap in the appearance of metastases and hepatocellular carcinoma (HCC). [21] On a case-by-case basis, clinical and ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC). These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium ...